{"id":"alpharadin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Xofigo","Radium-223 chloride","Radium-223 dichloride"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T05:53:12.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Malignant tumor of prostate","diseaseId":"malignant-tumor-of-prostate","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT04071236","phase":"PHASE1, PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":90},{"nctId":"NCT04071223","phase":"PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-29","conditions":"Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":134},{"nctId":"NCT03344211","phase":"PHASE2","title":"Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-11-21","conditions":"Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer","enrollment":30},{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":921},{"nctId":"NCT03317392","phase":"PHASE1, PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":145},{"nctId":"NCT04489719","phase":"","title":"Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2021-04-16","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma","enrollment":48},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT00337155","phase":"PHASE2","title":"BAY88-8223, Dose Finding Study in Patients With HRPC","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-05","conditions":"Prostate Cancer, Neoplasm Metastasis","enrollment":122},{"nctId":"NCT00667199","phase":"PHASE2","title":"BAY88-8223, Does Response Study in HRPC Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-05-30","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":100},{"nctId":"NCT02135484","phase":"NA","title":"Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09-19","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT01833520","phase":"PHASE1, PHASE2","title":"Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-16","conditions":"Sarcoma","enrollment":18},{"nctId":"NCT02199197","phase":"PHASE2","title":"Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-06-25","conditions":"Prostate Cancer","enrollment":49},{"nctId":"NCT03368989","phase":"","title":"The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-02-11","conditions":"Bony Metastases From Castrate Refractory Prostate Cancer","enrollment":21},{"nctId":"NCT01798108","phase":"PHASE1","title":"Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-08-14","conditions":"Neoplasm Metastasis","enrollment":31},{"nctId":"NCT01618370","phase":"PHASE3","title":"Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-07-22","conditions":"Prostatic Neoplasms","enrollment":705},{"nctId":"NCT01106352","phase":"PHASE1, PHASE2","title":"A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":"Bone Metastases, Castration-Resistant Prostate Cancer","enrollment":70},{"nctId":"NCT00667537","phase":"PHASE1","title":"PK in Pts With HRPC & Skeletal Metastes","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-07","conditions":"Prostatic Neoplasms","enrollment":6},{"nctId":"NCT01516762","phase":"","title":"Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","status":"NO_LONGER_AVAILABLE","sponsor":"Bayer","startDate":"","conditions":"Prostatic Neoplasms","enrollment":""},{"nctId":"NCT01070485","phase":"PHASE2","title":"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Breast Cancer, Bone Metastases","enrollment":23},{"nctId":"NCT00748046","phase":"PHASE1","title":"Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":"Prostate Cancer, Metastases, Pharmacokinetics","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":73,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Alpharadin","genericName":"Alpharadin","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}